<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463409</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 150497</org_study_id>
    <nct_id>NCT02463409</nct_id>
  </id_info>
  <brief_title>Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)</brief_title>
  <official_title>Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test an investigational drug, theophylline, in children with
      pseudohypoparathyroidism type 1a (PHP1a). This study involves a 3 day visit to the Vanderbilt
      Clinical Research Center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study measures will be done at baseline and during a 24h infusion of IV theophylline.
      Theophylline levels will be drawn to ensure therapeutic dosing and to monitor for toxicity.
      Measures include laboratory values, response to PTH infusion and resting energy expenditure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urine cAMP</measure>
    <time_frame>1 day</time_frame>
    <description>Change in urine cAMP (after parathyroid hormone stimulation) before and during treatment with theophylline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Resting Energy Expenditure (REE)</measure>
    <time_frame>1 day</time_frame>
    <description>Change in REE before and during treatment with theophylline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apnea Hypopnea Index (AHI)</measure>
    <time_frame>1 day</time_frame>
    <description>Change in AHI before and during treatment with theophylline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pseudohypoparathyroidism Type 1a</condition>
  <condition>Albright Hereditary Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>Theophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a 24 hour continuous infusion of intravenous theophylline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>24 hour infusion of IV theophylline</description>
    <arm_group_label>Theophylline</arm_group_label>
    <other_name>Theo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 10 to 21 years old

          2. English proficiency

          3. Clinical and genetic diagnosis of PHP1a

        Exclusion Criteria:

          1. Use of a PDE inhibitor in the past 30 days

          2. History of a seizure disorder unrelated to hypocalcemia

          3. History of a cardiac arrhythmia (not including bradycardia)

          4. History of hepatic insufficiency

          5. AST or ALT &gt;2x upper limit of normal

          6. Total bilirubin &gt;1.5 x upper limit of normal (unless patient has a diagnosis of
             Gilbert's syndrome and no other causes leading to hyperbilirubinemia are identified)

          7. Congestive heart failure

          8. Cigarette use in the past 30 days

          9. Alcohol use within the past 24 hours

         10. Current pregnancy

         11. Untreated hypothyroidism (defined as free T4 level &lt; 0.6 ng/dL or TSH &gt;10 mcU/mL)

         12. Active peptic ulcer disease

         13. Fever &gt;101 degrees in the past 24 hours

         14. Current use of medications known to effect theophylline levels (listed below)

         15. Severe sleep apnea requiring BiPAP

        Drugs with clinically significant drug interactions with theophylline:

          -  Allopurinol

          -  Cimetidine

          -  Ciprofloxacin

          -  Clarithromycin

          -  Enoxacin

          -  Ephedrine

          -  Erythromycin

          -  Estrogen

          -  Flurazepam

          -  Fluvoxamine

          -  Lithium

          -  Lorazepam

          -  Methotrexate

          -  Midazolam

          -  Pentoxifylline

          -  Propranolol

          -  Rifampin

          -  Sulfinpyrazone

          -  Tacrine

          -  Thiabendazole

          -  Ticlopidine

          -  Troleandomycin

          -  Verapamil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley H Shoemaker, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Unversity</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.facebook.com/pseudohypoparathyroidism</url>
    <description>Vanderbilt PHP Research Page</description>
  </link>
  <reference>
    <citation>Landreth H, Malow BA, Shoemaker AH. Increased Prevalence of Sleep Apnea in Children with Pseudohypoparathyroidism Type 1a. Horm Res Paediatr. 2015;84(1):1-5. doi: 10.1159/000381452. Epub 2015 Apr 23.</citation>
    <PMID>25925491</PMID>
  </reference>
  <reference>
    <citation>Shoemaker AH, Lomenick JP, Saville BR, Wang W, Buchowski MS, Cone RD. Energy expenditure in obese children with pseudohypoparathyroidism type 1a. Int J Obes (Lond). 2013 Aug;37(8):1147-53. doi: 10.1038/ijo.2012.200. Epub 2012 Dec 11.</citation>
    <PMID>23229731</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <results_first_submitted>April 19, 2017</results_first_submitted>
  <results_first_submitted_qc>April 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Ashley Shoemaker</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudohypoparathyroidism</mesh_term>
    <mesh_term>Pseudopseudohypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Investigators may contact Dr. Shoemaker for data after our primary analysis is completed and published (if applicable).</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The screening visit included labs, physical exam and medical history, prior to assignment to the theophylline arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Theophylline</title>
          <description>Patients will receive a 24 hour continuous infusion of intravenous theophylline.
Theophylline: 24 hour infusion of IV theophylline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients who enrolled in the study, not including screen fails</population>
      <group_list>
        <group group_id="B1">
          <title>Theophylline</title>
          <description>Patients will receive a 24 hour continuous infusion of intravenous theophylline.
Theophylline: 24 hour infusion of IV theophylline</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Urine cAMP</title>
        <description>Change in urine cAMP (after parathyroid hormone stimulation) before and during treatment with theophylline</description>
        <time_frame>1 day</time_frame>
        <population>Patients treated with theophylline who maintained appropriate IV access. Only 3 patients had complete data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Theophylline</title>
            <description>Patients will receive a 24 hour continuous infusion of intravenous theophylline.
Theophylline: 24 hour infusion of IV theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urine cAMP</title>
          <description>Change in urine cAMP (after parathyroid hormone stimulation) before and during treatment with theophylline</description>
          <population>Patients treated with theophylline who maintained appropriate IV access. Only 3 patients had complete data available.</population>
          <units>fm/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3048" spread="8369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Resting Energy Expenditure (REE)</title>
        <description>Change in REE before and during treatment with theophylline</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Theophylline</title>
            <description>Patients will receive a 24 hour continuous infusion of intravenous theophylline.
Theophylline: 24 hour infusion of IV theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Resting Energy Expenditure (REE)</title>
          <description>Change in REE before and during treatment with theophylline</description>
          <units>kcals per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14" spread="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Apnea Hypopnea Index (AHI)</title>
        <description>Change in AHI before and during treatment with theophylline</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Theophylline</title>
            <description>Patients will receive a 24 hour continuous infusion of intravenous theophylline.
Theophylline: 24 hour infusion of IV theophylline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apnea Hypopnea Index (AHI)</title>
          <description>Change in AHI before and during treatment with theophylline</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 days</time_frame>
      <desc>We specifically asked patients about headache, nausea and vomiting at least twice daily. They were monitored continuously via telemetry for arrhythmia. Other adverse events were reported as described by the partiicipant.</desc>
      <group_list>
        <group group_id="E1">
          <title>Theophylline</title>
          <description>Patients will receive a 24 hour continuous infusion of intravenous theophylline.
Theophylline: 24 hour infusion of IV theophylline. All patients who enrolled in the study are included in this group (excluding screen fails).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ashley Shoemaker</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-343-8816 ext 615</phone>
      <email>ashley.h.shoemaker@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

